Literature DB >> 17917053

Multiple roles of TRAF3 signaling in lymphocyte function.

Gail A Bishop1, Ping Xie.   

Abstract

Members of the tumor necrosis factor receptor (TNFR) superfamily employ cytoplasmic adapter proteins called TNF-R associated factors (TRAF) to initiate and regulate signaling pathways. Although many of these receptors associate with TRAF3, it has been unclear how this TRAF functions in immune responses. New information appearing through the use of novel experimental models reveals that TRAF3 can mediate both activating and inhibitory signals, and can participate in regulation of multiple members of the TNFR superfamily. TRAF3 is also important for signaling via innate immune receptors, as well as an oncogenic mimic of a normal receptor that is implicated in promoting both malignancies and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917053     DOI: 10.1007/s12026-007-0068-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  68 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 2.  Toll-like receptor signaling.

Authors:  Shizuo Akira
Journal:  J Biol Chem       Date:  2003-07-30       Impact factor: 5.157

3.  A novel RING finger protein interacts with the cytoplasmic domain of CD40.

Authors:  H M Hu; K O'Rourke; M S Boguski; V M Dixit
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

4.  TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production.

Authors:  Liang-Guo Xu; Hong-Bing Shu
Journal:  J Immunol       Date:  2002-12-15       Impact factor: 5.422

5.  LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3.

Authors:  ShuangDing Wu; Ping Xie; Kate Welsh; Chenglong Li; Chao-Zhou Ni; Xiuwen Zhu; John C Reed; Arnold C Satterthwait; Gail A Bishop; Kathryn R Ely
Journal:  J Biol Chem       Date:  2005-07-11       Impact factor: 5.157

6.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.

Authors:  I M de Alboran; R C O'Hagan; F Gärtner; B Malynn; L Davidson; R Rickert; K Rajewsky; R A DePinho; F W Alt
Journal:  Immunity       Date:  2001-01       Impact factor: 31.745

7.  The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells.

Authors:  I A Rooney; K D Butrovich; A A Glass; S Borboroglu; C A Benedict; J C Whitbeck; G H Cohen; R J Eisenberg; C F Ware
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

8.  TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.

Authors:  Julia Hauer; Stephanie Püschner; Parameswaran Ramakrishnan; Ute Simon; Martina Bongers; Christine Federle; Hartmut Engelmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-11       Impact factor: 11.205

9.  Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation.

Authors:  O Devergne; E Hatzivassiliou; K M Izumi; K M Kaye; M F Kleijnen; E Kieff; G Mosialos
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

10.  Molecular basis for CD40 signaling mediated by TRAF3.

Authors:  C Z Ni; K Welsh; E Leo; C K Chiou; H Wu; J C Reed; K R Ely
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

View more
  21 in total

Review 1.  Immunology at the University of Iowa.

Authors:  Gail A Bishop
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 2.  Roles of TRAF6 in CD40 signaling.

Authors:  Bruce S Hostager
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 3.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 4.  Roles of TRAF3 in T cells: many surprises.

Authors:  Zuoan Yi; Alicia M Wallis; Gail A Bishop
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 5.  TLR3 immunity to infection in mice and humans.

Authors:  Shen-Ying Zhang; Melina Herman; Michael J Ciancanelli; Rebeca Pérez de Diego; Vanessa Sancho-Shimizu; Laurent Abel; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2013-01-03       Impact factor: 7.486

6.  Nuclear TRAF3 is a negative regulator of CREB in B cells.

Authors:  Nurbek Mambetsariev; Wai W Lin; Laura L Stunz; Brett M Hanson; Joanne M Hildebrand; Gail A Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-11       Impact factor: 11.205

7.  Intracellular Signaling Pathways in Rheumatoid Arthritis.

Authors:  Charles J Malemud
Journal:  J Clin Cell Immunol       Date:  2013-08-19

Review 8.  Non-canonical NF-κB signaling pathway.

Authors:  Shao-Cong Sun
Journal:  Cell Res       Date:  2010-12-21       Impact factor: 25.617

9.  Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis.

Authors:  Rebeca Pérez de Diego; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Anne Puel; Sabine Plancoulaine; Capucine Picard; Melina Herman; Annabelle Cardon; Anne Durandy; Jacinta Bustamante; Sivakumar Vallabhapurapu; Jerónimo Bravo; Klaus Warnatz; Yves Chaix; Françoise Cascarrigny; Pierre Lebon; Flore Rozenberg; Michael Karin; Marc Tardieu; Saleh Al-Muhsen; Emmanuelle Jouanguy; Shen-Ying Zhang; Laurent Abel; Jean-Laurent Casanova
Journal:  Immunity       Date:  2010-09-09       Impact factor: 31.745

10.  Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile.

Authors:  Esther Lutgens; Dirk Lievens; Linda Beckers; Erwin Wijnands; Oliver Soehnlein; Alma Zernecke; Tom Seijkens; David Engel; Jack Cleutjens; Anna M Keller; Shalin H Naik; Louis Boon; Hafid Ait Oufella; Ziad Mallat; Cory L Ahonen; Randolph J Noelle; Menno P de Winther; Mat J Daemen; Erik A Biessen; Christian Weber
Journal:  J Exp Med       Date:  2010-01-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.